Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Electromed Inc to Release Quarterly Earnings Report

Elaine Mendonca by Elaine Mendonca
February 12, 2024
in Breaking News
0
Healthcare-IT-and-tech
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Electromed, Inc. (ELMD) is scheduled to release its latest quarterly earnings report on February 13, 2024. Analysts predict that the company will announce an earnings per share (EPS) of $0.10.

In the previous quarter, Electromed fell short of the expected EPS by $0.08. Surprisingly, this setback was followed by a 2.09% rise in the share price the following day. It’s worth noting that the stock price of a company is not solely influenced by an earnings beat or miss, but also by the guidance or forecast provided.

Over the past 12 months, Electromed has accumulated a total revenue of $48.07M, indicating a 15.38% increase compared to the previous year. However, there has been a 9.46% decrease in revenue since the last quarter. The net income for the past 12 months stands at $3.17M.

If you require more comprehensive information regarding Electromed’s earnings, you can visit Nasdaq.com for detailed annual and quarterly earnings data. Moreover, Simply Wall St. offers a comprehensive stock overview, encompassing historical stock prices and performance for the company.

Analyzing Electromed, Inc. (ELMD) Stock Performance: Factors to Consider for Investors and Traders

On February 12, 2024, the stock performance of Electromed, Inc. (ELMD) was analyzed. It was found that the stock was trading in the middle of its 52-week range and below its 200-day simple moving average. The stock’s price dropped by $0.04 since the market last closed, representing a 0.42% decrease. The stock opened at $10.33, $0.05 lower than its previous close. Investors and traders should consider these factors when making decisions regarding ELMD stock.

Examining the Stock Performance of Electro Medical Devices (ELMD) on February 12, 2024: Insights into Financial Health and Recent Performance

On February 12, 2024, the stock performance of Electro Medical Devices (ELMD) is worth examining. By analyzing the data provided by CNN Money, we can gain insights into the company’s financial health and its recent performance.

Total revenue plays a crucial role in evaluating a company’s financial performance. In the past year, ELMD generated a total revenue of $48.07 million, which is an increase of 15.38% compared to the previous year. However, when compared to the previous quarter, the total revenue has decreased by 9.46%, standing at $12.32 million.

The net income of ELMD is another important metric to consider. Over the past year, the company reported a net income of $3.17 million, reflecting a significant increase of 37.35% compared to the previous year. However, in the first quarter of 2024, the net income dropped by 85.0% to $155.00 thousand.

Earnings per share (EPS) is a key indicator of a company’s profitability. ELMD reported an EPS of $0.36 in the past year, representing a growth of 38.42% compared to the previous year. However, in the first quarter of 2024, the EPS plummeted by 85.14% to $0.02.

Analyzing these numbers, it is clear that ELMD has experienced mixed results in terms of its financial performance. While the company managed to achieve a significant increase in total revenue and net income over the past year, the first quarter of 2024 saw a decline in both metrics. This decline is also reflected in the earnings per share, which experienced a sharp drop.

Investors and analysts will closely monitor these figures to understand the reasons behind the decline in the first quarter of 2024. It is important to consider various factors that may have contributed to this decline, including market conditions, competition, and internal factors within the company.

ELMD’s management team will likely be focused on implementing strategies to address the decrease in revenue and net income. They may explore opportunities to increase sales, reduce expenses, or improve operational efficiency to drive growth in the coming quarters.

Investors should exercise caution when considering ELMD as an investment option. It is crucial to conduct thorough research and analysis to understand the company’s overall financial health and its ability to navigate challenges in the industry.

In conclusion, the stock performance of ELMD on February 12, 2024, indicates a mixed financial performance. While the company experienced growth in total revenue, net income, and earnings per share over the past year, the first quarter of 2024 saw a decline in these metrics. Investors should closely monitor the company’s future performance and evaluate the strategies implemented by its management team to determine the potential for future growth.

Tags: ELMD
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Insurance Stock Exchange

Analyst Consensus and Price Target for Lincoln National Corporation LNC

Technology Data analytics stock Trading

WiMi Hologram Cloud Inc Unveils Revolutionary PBFT Algorithm for Blockchain Systems

Healthcare Services Stock Exchange

Renalytix PLCs Stock Soars After Exciting Announcement on CMS Draft LCD

Recommended

FCBC stock news

Impax Asset Management Group plc Reduces Stake in Snap Inc. as Insiders Sell Off Shares

2 years ago
The Trade Desk Stock

The Trade Desk: A Market Conundrum of Conflicting Signals

3 months ago
Intel Stock

US Government Holds Massive Intel Share Position, Creating Market Uncertainty

5 months ago
Nuvalent Stock

Nuvalent Shares Surge on Promising Clinical Trial Results

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Trending

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

by Kennethcix
February 8, 2026
0

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations...

Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
RBB Stock

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit
  • SuRo Capital Sharpens Focus on AI Infrastructure Investments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com